2008
DOI: 10.1016/j.bmcl.2008.08.112
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2009
2009
2019
2019

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(4 citation statements)
references
References 23 publications
0
4
0
Order By: Relevance
“…N -alkylation of the commercially available key intermediate 12 with custom synthesized [4-(4-fluorophenyl)­butyl] methanesulfonate afforded intermediate 13 in 49% yield. Further treatment with BBr 3 yielded phenolic reference compound 14 (PF-NB1) in 61% yield.…”
Section: Resultsmentioning
confidence: 99%
“…N -alkylation of the commercially available key intermediate 12 with custom synthesized [4-(4-fluorophenyl)­butyl] methanesulfonate afforded intermediate 13 in 49% yield. Further treatment with BBr 3 yielded phenolic reference compound 14 (PF-NB1) in 61% yield.…”
Section: Resultsmentioning
confidence: 99%
“…Vallejos et al [10] reported the experimental investigation of the structure and vibrational properties of methoxycarbonylsulfenyl isocyanate. Pingali et al [11] reported a highly orally bio available sulfonyl derivative as a potent hypoglycaemic and hypolipidemic agent. Yang et al [12] reported the new preparation of difluoroiodomethylsulfanylbenzenes and their radical addition to unsaturated compounds initiated by sodium dithionite.…”
Section: Introductionmentioning
confidence: 99%
“…Yang et al [8] reported a new method of preparation of difluoroiodomethylsulfanylbenzenes and their radical addition to unsaturated compounds initiated by sodium dithionite. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-α converting enzyme and matrix metalloproteinase inhibitors were reported by Venkatesan et al [9] Pingali et al [10] reported the highly orally bioavailable c-5- [6-(4-methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. The synthesis of a series of 2-benzenesulfonylalkyl-5-substituted-sulfanyl- [1,3,4]oxadiazoles and the examination of their anti-hepatitis B virus activity have also been reported.…”
Section: Introductionmentioning
confidence: 98%